The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in Apolipoprotein E knockout mice

International Journal of Molecular Sciences

Volumn 15, Issue 7, 2014, Pages 11416-11434

  Li, Jingjing ^a   Guan, Meiping ^a   Li, Chenzhong ^a   Lyv, Fuping ^a   Zeng, Yanmei ^a   Zheng, Zongji ^a   Wang, Chengzhi ^a   Xue, Yaoming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Akt; AMPK; Dyslipidemia; FN; HFD; Kidney injury; p38 ERK MAPK; Sitagliptin; TGF 1

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; APOLIPOPROTEIN E; CHOLESTEROL; FIBRONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPID; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SITAGLIPTIN; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOWN REGULATION; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FROZEN SECTION; GLUCOSE TOLERANCE TEST; HISTOLOGY; INSULIN SENSITIVITY; KIDNEY INJURY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ACUTE KIDNEY INJURY; ANIMAL; C57BL MOUSE; COMPLICATION; DYSLIPIDEMIAS; GENETICS; KIDNEY; MALE; METABOLISM;

ACUTE KIDNEY INJURY; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOLIPOPROTEINS E; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DYSLIPIDEMIAS; FIBRONECTINS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; TRANSFORMING GROWTH FACTOR BETA1; TRIAZOLES;

EID: 84903386097     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150711416     Document Type: Article

References (60)

1. Anderson, S.; King, A. J.; Brenner, B. M. Hyperlipidemia and glomerular sclerosis: An alternative viewpoint. Am. J. Med. 1989, 87, 34N-38N.
2. Attman, P. O.; Alaupovic, P.; Samuelsson, O. Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. Kidney Int. Suppl. 1999, 71, S14-S17.
3. Trevisan, R.; Dodesini, A. R.; Lepore, G. Lipids and renal disease. J. Am. Soc. Nephrol. 2006, 17, S145-S147.
4. Appel, G. Lipid abnormalities in renal disease. Kidney Int. 1991, 39, 169-183.
5. Samuelsson, O.; Mulec, H.; Knight-Gibson, C.; Attman, P. O.; Kron, B.; Larsson, R.; Weiss, L.; Wedel, H.; Alaupovic, P. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol. Dial. Transplant. 1997, 12, 1908-1915.
6. Hunsicker, L. G.; Adler, S.; Caggiula, A.; England, B. K.; Greene, T.; Kusek, J. W.; Rogers, N. L.; Teschan, P. E. Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int. 1997, 51, 1908-1919.
7. Maschio, G.; Oldrizzi, L.; Rugiu, C.; Loschiavo, C. Serum lipids in patients with chronic renal failure on long-term, protein-restricted diets. Am. J. Med. 1989, 87, 51N-54N.
8. Wen, M.; Segerer, S.; Dantas, M.; Brown, P. A.; Hudkins, K. L.; Goodpaster, T.; Kirk, E.; LeBoeuf, R. C.; Alpers, C. E. Renal injury in apolipoprotein E-deficient mice. Lab. Investig. 2002, 82, 999-1006.
9. Decleves, A. E.; Mathew, A. V.; Cunard, R.; Sharma, K. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J. Am. Soc. Nephrol. 2011, 22, 1846-1855.
10. Sharma, K.; Ramachandrarao, S.; Qiu, G.; Usui, H. K.; Zhu, Y.; Dunn, S. R.; Ouedraogo, R.; Hough, K.; McCue, P.; Chan, L.; et al. Adiponectin regulates albuminuria and podocyte function in mice. J. Clin. Investig. 2008, 118, 1645-1656.
11. Nangaku, M. Energy policy of the kidney: Launch of AMPK as a novel therapeutic target. Am. J. Physiol. Renal. Physiol. 2013, 305, F977-F978.
12. Satriano, J.; Sharma, K.; Blantz, R. C.; Deng, A. Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease. Am. J. Physiol. Renal. Physiol. 2013, 305, F727-F733.
13. Lee, M. J.; Feliers, D.; Mariappan, M. M.; Sataranatarajan, K.; Mahimainathan, L.; Musi, N.; Foretz, M.; Viollet, B.; Weinberg, J. M.; Choudhury, G. G.; et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am. J. Physiol. Renal. Physiol. 2007, 292, F617-F627.
14. Kovacic, S.; Soltys, C. L.; Barr, A. J.; Shiojima, I.; Walsh, K.; Dyck, J. R. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J. Biol. Chem. 2003, 278, 39422-39427.
15. Dhillon, S. Sitagliptin: A review of its use in the management of type 2 diabetes mellitus. Drugs 2010, 70, 489-512.
16. Baggio, L. L.; Drucker, D. J. Harnessing the therapeutic potential of glucagon-like peptide-1: A critical review. Treat. Endocrinol. 2002, 1, 117-125.
17. Usdin, T. B.; Mezey, E.; Button, D. C.; Brownstein, M. J.; Bonner, T. I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993, 133, 2861-2870.
18. Baggio, L. L.; Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132, 2131-2157.
19. Monami, M.; Lamanna, C.; Desideri, C. M.; Mannucci, E. DPP-4 inhibitors and lipids: Systematic review and meta-analysis. Adv. Ther. 2012, 29, 14-25.
20. Parlevliet, E. T.; Wang, Y.; Geerling, J. J.; Schroder-Van, D. E. J.; Picha, K.; O'Neil, K.; Stojanovic-Susulic, V.; Ort, T.; Havekes, L. M.; Romijn, J. A.; et al. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One 2012, 7, e49152.
21. Tremblay, A. J.; Lamarche, B.; Deacon, C. F.; Weisnagel, S. J.; Couture, P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes. Metab. 2011, 13, 366-373.
22. Hsieh, J.; Longuet, C.; Baker, C. L.; Qin, B.; Federico, L. M.; Drucker, D. J.; Adeli, K. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2012, 53, 552-561.
23. Fujita, H.; Taniai, H.; Murayama, H.; Ohshiro, H.; Hayashi, H.; Sato, S.; Kikuchi, N.; Komatsu, T.; Komatsu, K.; Komatsu, K.; et al. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy. Endocr. J. 2014, 61, 159-166.
24. Mega, C.; de Lemos, E. T.; Vala, H.; Fernandes, R.; Oliveira, J.; Mascarenhas-Melo, F.; Teixeira, F.; Reis, F. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp. Diabetes Res. 2011, 2011, 162092.
25. Liu, W. J.; Xie, S. H.; Liu, Y. N.; Kim, W.; Jin, H. Y.; Park, S. K.; Shao, Y. M.; Park, T. S. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther. 2012, 340, 248-255.
26. Joo, K. W.; Kim, S.; Ahn, S. Y.; Chin, H. J.; Chae, D. W.; Lee, J.; Han, J. S.; Na, K. Y. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney. BMC Nephrol. 2013, 14, 98.
27. Chen, Y. T.; Tsai, T. H.; Yang, C. C.; Sun, C. K.; Chang, L. T.; Chen, H. H.; Chang, C. L.; Sung, P. H.; Zhen, Y. Y.; Leu, S.; et al. Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J. Transl. Med. 2013, 11, 270.
28. Moorhead, J. F.; Chan, M. K.; El-Nahas, M.; Varghese, Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982, 2, 1309-1311.
29. Kees-Folts, D.; Diamond, J. R. Relationship between hyperlipidemia, lipid mediators, and progressive glomerulosclerosis in the nephrotic syndrome. Am. J. Nephrol. 1993, 13, 365-375.
30. Schaeffner, E. S.; Kurth, T.; Curhan, G. C.; Glynn, R. J.; Rexrode, K. M.; Baigent, C.; Buring, J. E.; Gaziano, J. M. Cholesterol and the risk of renal dysfunction in apparently healthy men. J. Am. Soc. Nephrol. 2013, 14, 2084-2091.
31. Taneda, S.; Hudkins, K. L.; Cui, Y.; Farr, A. G.; Alpers, C. E.; Segerer, S. Growth factor expression in a murine model of cryoglobulinemia. Kidney Int. 2003, 63, 576-590.
32. Viollet, B.; Foretz, M.; Guigas, B.; Horman, S.; Dentin, R.; Bertrand, L.; Hue, L.; Andreelli, F. Activation of AMP-activated protein kinase in the liver: A new strategy for the management of metabolic hepatic disorders. J. Physiol. 2006, 574, 41-53.
33. Zeng, Y.; Li, C.; Guan, M.; Zheng, Z.; Li, J.; Xu, W.; Wang, L.; He, F.; Xue, Y. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPKand MAPK-dependent mechanisms. Cardiovasc. Diabetol. 2014, 13, 32.
34. Rask-Madsen, C.; Li, Q.; Freund, B.; Feather, D.; Abramov, R.; Wu, I. H.; Chen, K.; Yamamoto-Hiraoka, J.; Goldenbogen, J.; Sotiropoulos, K. B.; et al. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab. 2012, 11, 379-89.
35. Matsubara, J.; Sugiyama, S.; Sugamura, K.; Nakamura, T.; Fujiwara, Y.; Akiyama, E.; Kurokawa, H.; Nozaki, T.; Ohba, K.; Konishi, M.; et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J. Am. Coll. Cardiol. 2012, 59, 265-276.
36. Deacon, C. F.; Holst, J. J. Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: A historical perspective. Biochem. Biophys. Res. Commun. 2002, 294, 1-4.
37. Conarello, S. L.; Li, Z.; Ronan, J.; Roy, R. S.; Zhu, L.; Jiang, G.; Liu, F.; Woods, J.; Zycband, E.; Moller, D. E.; et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 2003, 100, 6825-6830.
38. Fujita, H.; Morii, T.; Fujishima, H.; Sato, T.; Shimizu, T.; Hosoba, M.; Tsukiyama, K.; Narita, T.; Takahashi, T.; Drucker, D. J.; et al. The protective roles of GLP-1R signaling in diabetic nephropathy: Possible mechanism and therapeutic potential. Kidney Int. 2014, 85, 579-589.
39. Ishibashi, Y.; Nishino, Y.; Matsui, T.; Takeuchi, M.; Yamagishi, S. Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism 2011, 60, 1271-1277.
40. Walker, P. D.; Kaushal, G. P.; Shah, S. V. Meprin A, the major matrix degrading enzyme in renal tubules, produces a novel nidogen fragment in vitro and in vivo. Kidney Int. 1998, 53, 1673-1680.
41. Nogueira-Machado, J. A.; Volpe, C. M.; Veloso, C. A.; Chaves, M. M. HMGB1, TLR and RAGE: A functional tripod that leads to diabetic inflammation. Expert Opin. Ther. Targets 2011, 15, 1023-1035.
42. Hocher, B.; Reichetzeder, C.; Alter, M. L. Renal and cardiac effects of DPP4 inhibitors-From preclinical development to clinical research. Kidney Blood Press. Res. 2012, 36, 65-84.
43. Jin, H. Y.; Liu, W. J.; Park, J. H.; Baek, H. S.; Park, T. S. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch. Med. Res. 2009, 40, 536-544.
44. Abd, E. M. D.; Elshazly, S. M. Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: Role of GLP-1 and GLP-1 receptor. Eur. J. Pharmacol. 2013, 720, 158-165.
45. Munoz-Garcia, B.; Moreno, J. A.; Lopez-Franco, O.; Sanz, A. B.; Martin-Ventura, J. L.; Blanco, J.; Jakubowski, A.; Burkly, L. C.; Ortiz, A.; Egido, J.; et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 2061-2068.
46. Manson, S. R.; Song, J. B.; Hruska, K. A.; Austin, P. F. HDAC dependent transcriptional repression of BMP-7 potentiates TGF-β mediated renal fibrosis in obstructive uropathy. J. Urol. 2014, 191, 242-252.
47. Huang, X.; Wen, D.; Zhang, M.; Xie, Q.; Ma, L.; Guan, Y.; Ren, Y.; Chen, J.; Hao, C. M. Sirt1 activation ameliorates renal fibrosis by inhibiting the TGF-β/Smad3 pathway. J. Cell. Biochem. 2014, doi: 10. 1002/jcb. 24748.
48. Lopez-Hernandez, F. J.; Lopez-Novoa, J. M. Role of TGF-β in chronic kidney disease: An integration of tubular, glomerular and vascular effects. Cell Tissue Res. 2012, 347, 141-154.
49. Chen, Z. X.; Xie, X. Y.; Yu, R. C.; Zhang, J.; Lei, M. X. Hyperlipidemia induced by high fat diet ingestion activates TGF-β/Smad signaling pathway in the kidney of diabetic rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008, 33, 906-912. (In Chinese).
50. Yanagita, M. Inhibitors/antagonists of TGF-β system in kidney fibrosis. Nephrol. Dial. Transplant. 2012, 27, 3686-3691.
51. Kato, M. TGF-β-induced signaling circuit loops mediated by microRNAs as new therapeutic targets for renal fibrosis? Kidney Int. 2013, 84, 1067-1069.
52. Liu, N.; He, S.; Ma, L.; Ponnusamy, M.; Tang, J.; Tolbert, E.; Bayliss, G.; Zhao, T. C.; Yan, H.; Zhuang, S. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-β and EGFR signaling. PLoS One 2013, 8, e54001.
53. Meng, X. M.; Chung, A. C.; Lan, H. Y. Role of the TGF-β/BMP-7/Smad pathways in renal diseases. Clin. Sci. 2013, 124, 243-254.
54. Lan, H. Y. Diverse roles of TGF-β/Smads in renal fibrosis and inflammation. Int. J. Biol. Sci. 2011, 7, 1056-1067.
55. Dai, Y.; Palade, P.; Wang, X.; Mercanti, F.; Ding, Z.; Dai, D.; Mehta, J. L. High fat diet causes renal fibrosis in LDLr-null mice through MAPK-NF-κB pathway mediated by Ox-LDL. J. Cardiovasc. Pharmacol. 2014, 63, 158-166.
56. Gao, X.; Wu, G.; Gu, X.; Fu, L.; Mei, C. Kruppel-like factor 15 modulates renal interstitial fibrosis by ERK/MAPK and JNK/MAPK pathways regulation. Kidney Blood Press. Res. 2013, 37, 631-640.
57. Ma, X. H.; Zou, Y.; Zhang, Y.; He, L. Q. MAPK p38 pathway may be involved in renal function improvement in chronic renal failure rats treated with Jianpi Qinghua decoction. Zhejiang Da Xue Xue Bao Yi Xue Ban 2013, 42, 567-572. (In Chinese).
58. Zdychova, J.; Komers, R. Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications. Physiol. Res. 2005, 54, 1-16.
59. Chung, H. W.; Lim, J. H.; Kim, M. Y.; Shin, S. J.; Chung, S.; Choi, B. S.; Kim, H. W.; Kim, Y. S.; Park, C. W.; Chang, Y. S. High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α pathway. Nephrol. Dial. Transplant. 2012, 27, 2213-2225.
60. Decleves, A. E.; Zolkipli, Z.; Satriano, J.; Wang, L.; Nakayama, T.; Rogac, M.; Le, T. P.; Nortier, J. L.; Farquhar, M. G.; Naviaux, R. K.; et al. Regulation of lipid accumulation by AMK-activated kinase in high fat diet-induced kidney injury. Kidney Int. 2014, 85, 611-623.